Deep-pocketed investors have adopted a bullish approach towards Moderna MRNA, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Moderna. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 41% bearish. Among these notable options, 3 are puts, totaling $141,090, and 9 are calls, amounting to $406,571.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $90.0 to $180.0 for Moderna over the last 3 months.
Analyzing Volume & Open Interest
In today's trading context, the average open interest for options of Moderna stands at 882.92, with a total volume reaching 590.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $90.0 to $180.0, throughout the last 30 days.
Moderna Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | CALL | SWEEP | BULLISH | 05/17/24 | $4.8 | $4.2 | $4.8 | $122.00 | $96.0K | 107 | 0 |
| MRNA | PUT | SWEEP | BULLISH | 06/20/25 | $8.85 | $8.8 | $8.8 | $90.00 | $85.3K | 322 | 148 |
| MRNA | CALL | TRADE | BEARISH | 06/20/25 | $11.85 | $11.7 | $11.7 | $180.00 | $58.5K | 0 | 0 |
| MRNA | CALL | TRADE | BEARISH | 01/17/25 | $26.3 | $25.7 | $25.94 | $110.00 | $51.8K | 838 | 0 |
| MRNA | CALL | SWEEP | BULLISH | 05/10/24 | $2.21 | $2.1 | $2.18 | $120.00 | $43.6K | 1.3K | 321 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Where Is Moderna Standing Right Now?
- With a trading volume of 1,630,459, the price of MRNA is up by 0.56%, reaching $122.82.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 86 days from now.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
